Research programme: anti-fibroproliferative small molecule therapeutics - Celgene/PharmAkea

Drug Profile

Research programme: anti-fibroproliferative small molecule therapeutics - Celgene/PharmAkea

Alternative Names: Cancer and fibrotic disease oral therapies - Celgene/PharmAkea; Fibroproliferative disease therapies - Celgene/PharmAkea

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmAkea Therapeutics
  • Developer Celgene Corporation; PharmAkea Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Connective tissue disorders

Most Recent Events

  • 18 Nov 2016 PharmAkea and Celgene Corporation extend the term of their agreement for fibrotic diseases
  • 04 Oct 2013 Early research in Cancer and Connective tissue disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top